Clinical trials: Oral Anticoagulants
Acute Ischemic Stroke
Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral Anticoagulant
The study will randomize patients with acute ischemic stroke and Direct Oral AntiCoagulants (DOAC) ingestion within 48 hours from enrollment (but otherwise eligible for thrombolysis) to administration of intravenous tenecteplase…
- Trial name
- ESTER-DOAC (NCT07621796)
- Testing
- Intravenous tenecteplase (TNK)
- Where
- United States
- Volunteers
- 660 people
- Sponsor
- Hackensack Meridian Health
Atrial Fibrillation
hsTnT in Patients Admitted to the ED With Atrial Fibrillation in the Era of NOACs - Heidelberg Registry of Atrial Fibrillation
The purpose of the Heidelberg Registry of Atrial Fibrillation (HERA-FIB) is to collect data on the prevalence and clinical significance of elevated cardiac troponin in a large registry of unselected patients with atrial…
- Trial name
- HERA-FIB (NCT03344237)
- Where
- Germany
- Volunteers
- 5,000 people
- Sponsor
- University Hospital Heidelberg
Cardioembolic Stroke, Anticoagulant Therapy
Keeping Oral o Parental AnticoaguLation in the Acute Phase of Cardioembolic Ischemic Stroke
This is an observational, prospective, multicenter, cohort study in patients with cardioembolic stroke and previous oral or parenteral anticoagulant therapy.
- Conditions
- Cardioembolic Stroke, Anticoagulant Therapy, Stroke Recurrence, Haemorrhagic Transformation Stroke
- Trial name
- KOALA-IS (NCT05486351)
- Testing
- Observation
- Where
- 3 sites in France, Spain
- Volunteers
- 318 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Gastrointestinal Hemorrhage, Diabetes Complications
Therapeutic Conflicts and Multimorbidity
Clinical practice guidelines do not take into account multimorbidity and various potential therapeutic conflicts. Identifying and quantifying therapeutic conflicts is crucial in multimorbid patients having more than two acute or…
- Conditions
- Gastrointestinal Hemorrhage, Diabetes Complications, Multimorbidity
- Trial name
- NCT02928939
- Testing
- drug-drug or drug-disease interaction
- Where
- Switzerland
- Volunteers
- 1,101 people
- Sponsor
- University of Zurich
Venous Thrombosis, Deep Vein Thrombosis
Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer
This is a multicenter, cohort study evaluating an adapted rivaroxaban dose regimen in patients with acute, proximal deep-vein thrombosis (DVT) or acute pulmonary embolism (PE) who concomitantly use a strong cytochrome P450…
- Trial name
- NCT00786422
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 16 sites in Australia, Austria and 7 more
- Volunteers
- 25 people
- Sponsor
- Bayer
Atrial Fibrillation, Thromboembolism, Venous
DOCE Study Interaction Between Direct Oral Anticoagulants and Drug-metabolizing Enzyme Inducers
Aim of the study is to investigate whether the influence of drugs inducing of CYP 3A4 isoenzyme of CYP450 and P-gp transporter significantly affect plasma levels of DOACs in patients with NVAF and venous thromboembolism
- Trial name
- NCT05750680
- Testing
- DOACs
- Where
- Italy
- Volunteers
- 23 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Venous Thromboembolism, Thromboembolism
A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
The objective of this study is to compare the efficacy, safety of DU-176b 30mg or DU-176b 15mg versus enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total hip arthroplasty.
- Conditions
- Venous Thromboembolism, Thromboembolism, Thrombosis, Embolism and Thrombosis
- Trial name
- NCT01203098
- Testing
- DU-176b 15mg, DU-176b 30mg, Enoxaparin sodium 20 mg (=2000IU)
- Where
- 3 sites in Japan, Taiwan
- Volunteers
- 264 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Atrial Fibrillation
Therapeutic Strategy with Direct Oral Anticoagulants and Antiaggregant Drugs in Ischemic Heart Disease
The study aims to depict the actual prescription patterns employed in clinical practice of patients affected by non-valvular atrial fibrillation undergoing percutaneous coronary intervention (i.e.
- Trial name
- PRODOAC (NCT06239402)
- Testing
- Observation
- Where
- Italy
- Volunteers
- 394 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Effect of NOAC on POCT
Ex-vivo Effect of New Oral Anticoagulants on Point-of-care Devices
Concentration determinations of anticoagulants require plasma instead of whole blood, and results are not immediately available to clinicians.
- Trial name
- NCT01613443
- Volunteers
- 100 people
- Sponsor
- Cardioangiologisches Centrum Bethanien
Blood Transfusion, Hip Fracture Surgeries
Hip Fracture Surgery Timing and Blood Transfusion Risk in Patients on DOACs
This study looks at patients with hip fractures who are taking direct oral anticoagulants (DOACs), a type of blood thinner. In many hospitals, surgery for these patients is delayed because of concerns about bleeding, but waiting…
- Conditions
- Blood Transfusion, Hip Fracture Surgeries, Geriatric, Bleeding Complications
- Trial name
- OPTIMIZEDOAC (NCT07309848)
- Where
- 7 sites in Netherlands
- Volunteers
- 374 people
- Sponsor
- St. Antonius Hospital
Healthcare Quality Indicators, Inappropriate Prescribing
Development and Validation of Automated Indicators on the Appropriateness of Oral Anticoagulant Prescriptions
This research focuses on the development and validation of indicators on the appropriateness of oral anticoagulant prescriptions.
- Conditions
- Healthcare Quality Indicators, Inappropriate Prescribing, Anticoagulant Drugs, Atrial Fibrillation
- Trial name
- PACHA (NCT02898090)
- Where
- 4 sites in France
- Volunteers
- 1,213 people
- Sponsor
- University Hospital, Bordeaux
Embolism, Thrombosis
Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach
Objectives are to evaluate whether idrabiotaparinux sodium (SSR126517E) is as least as effective as a standard warfarin treatment to prevent recurrence of venous thromboembolic events (VTE) in patients with symptomatic pulmonary…
- Trial name
- CASSIOPEA (NCT00345618)
- Testing
- Idrabiotaparinux sodium, Warfarin, Avidin
- Where
- 38 sites in United States, Argentina and 36 more
- Volunteers
- 3,202 people
- Sponsor
- Sanofi
Venous Thromboembolism
WHITE Study: WHIch Decision After a First Venous ThromboEmbolism?
The WHITE study is a multicenter, multinational, investigators-initiated, observational, prospective study conducted in a consecutive series of ambulatory patients who had completed the recommended or practicable period of…
- Trial name
- WHITE (NCT04646993)
- Where
- Czechia
- Volunteers
- 1,200 people
- Sponsor
- Arianna Anticoagulazione Foundation
Stroke, Systemic Embolism
NOAC Portuguese Real World Study
To determine if there is any difference in the effectiveness and safety outcomes of patients with NVAF newly treated with apixaban, dabigatran, rivaroxaban and vitamin K antagonists
- Conditions
- Stroke, Systemic Embolism, Major Bleeding
- Trial name
- NCT04808934
- Testing
- Apixaban, dabigatran, rivaroxaban
- Sponsor
- Pfizer
Atrial Fibrillation
PRescriptiOn PattERns Of Oral Anticoagulants
Atrial fibrillation is the major cause of acute ischemic stroke. The risk of stroke was shown to decline by oral anticoagulant therapy.
- Trial name
- PROPER (NCT02366338)
- Volunteers
- 148 people
- Sponsor
- Muğla Sıtkı Koçman University
Acute Ischemic Stroke
Intravenous Thrombolysis and NOAC
New oral anticoagulants (NOACs), including rivaroxaban, apixaban, dabigatran, and edoxaban, have become the first-line therapy for preventing ischemic stroke associated with non-valvular atrial fibrillation (NVAF).
- Trial name
- NCT06749834
- Testing
- Intravenous thrombolysis
- Where
- 2 sites in China
- Volunteers
- 280 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Cancer, Venous Thromboembolism
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients.
- Conditions
- Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)
- Trial name
- CANVAS (NCT02744092)
- Testing
- Rivaroxaban, Apixaban, Edoxaban
- Where
- 151 sites in United States
- Volunteers
- 811 people
- Sponsor
- Alliance Foundation Trials, LLC.
Non-valvular Atrial Fibrillation
Exploratory Observation of Two Short-term Regimens After LAA Occlusion by LAMax LAAC® Device for Subjects With Non-valvular Atrial Fibrillation
This is a prospective, single-center, randomized, exploratory clinical observation to explore the overall benefit of short-term dual antiplatelet or novel oral anticoagulant regimens after left atrial appendage (LAA) occlusion by…
- Trial name
- NCT05761704
- Testing
- Dual antiplatelet, Novel oral anticoagulant
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Femur Fracture
Assessment of a Procedure for Managing Oral Anticoagulants (NACO) in the Management of Fractures
The purpose of this study is to demonstrate that by allowing patients with an anticoagulant level less than 100 ng/ml to have their fracture managed surgically, will reduce the delay in surgery and therefore the complications…
- Trial name
- STOP-NACO (NCT06220422)
- Testing
- Standard Department procedure for managing direct-acting oral anticoagulants, New Department procedure for managing direct-acting oral anticoagulants
- Where
- France
- Volunteers
- 127 people
- Sponsor
- Hôpital NOVO
Deep Venous Thrombosis, Pulmonary Embolism
Drug Interaction Between Paracetamol and Warfarin
The objective of this study is to investigate whether paracetamol, given at therapeutic doses (2g/day and 3 g/day), may potentiate the anticoagulant effect of warfarin.
- Conditions
- Deep Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Stroke
- Trial name
- INPAWA2 (NCT01104337)
- Testing
- paracetamol
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Hopital Lariboisière